8-K: IN8bio Reports Positive Clinical Data and Second Quarter 2024 Financial Results Amidst Nasdaq Listing Compliance Concerns

IN8bio announced positive clinical trial results for its gamma-delta T cell therapies and its second quarter 2024 financial results, while also disclosing a Nasdaq notification regarding its stock price.

Summary

• IN8bio reported its second quarter 2024 financial results, showing a net loss of $8.6 million, or $0.19 per share, compared to a net loss of $7.7 million, or $0.27 per share, in the same period last year.
• The company's research and development expenses increased to $5.2 million from $4.1 million year-over-year, primarily due to increased personnel and clinical trial costs.
• General and administrative expenses remained relatively flat at $3.5 million.
• As of June 30, 2024, IN8bio had $10.2 million in cash, down from $21.3 million at the end of 2023.
• The company presented positive Phase 1 data for INB-100, showing 100% one-year complete remission in evaluable patients with hematologic malignancies.
• Additionally, 92% of glioblastoma patients treated with INB-200 exceeded the median seven-month progression-free survival with standard-of-care treatment.
• IN8bio received a notification from Nasdaq that its stock price had fallen below the minimum $1.00 requirement for 31 consecutive days and has until February 3, 2025, to regain compliance.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the clinical data is very positive, the financial results are concerning, and the Nasdaq listing issue is a significant risk. The positive clinical data is balanced by the negative financial and listing news.

Positives

• The company's INB-100 therapy demonstrated a 100% one-year complete remission rate in a Phase 1 trial for hematologic malignancies.
• INB-200 showed promising results in glioblastoma patients, with 92% exceeding the standard median progression-free survival.
• IN8bio's manufacturing platform for gamma-delta T cells is robust and reproducible.
• The safety profile of gamma-delta T cells remains strong with no cell therapy-related toxicities reported in Phase 1 trials.
• The company's gamma-delta T cell therapies have the potential to revolutionize cancer treatment.

Negatives

• The company experienced a net loss of $8.6 million in the second quarter of 2024.
• IN8bio's cash position decreased significantly to $10.2 million.
• The company received a Nasdaq notification for failing to maintain a minimum stock price of $1.00, putting its listing at risk.
• The company's net loss per share increased from $0.27 to $0.19 year-over-year.

Risks

• The company's stock price falling below $1.00 per share could lead to delisting from the Nasdaq Stock Market.
• There is a risk that IN8bio may not achieve the plans, intentions, or expectations disclosed in forward-looking statements.
• Clinical trials may be delayed and may not have satisfactory outcomes.
• The company relies on third parties, including licensors and clinical research organizations.
• There are risks associated with public health crises, rising inflation, and regulatory developments.

Future Outlook

The company looks forward to providing additional updates on its gamma-delta T cell programs as it generates longer patient follow-up and advances its pipeline. IN8bio intends to actively monitor the closing bid price of its common stock and will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price rule.

Management Comments

• William Ho, CEO and co-founder of IN8bio, stated that gamma-delta T cell therapies have the potential to revolutionize cancer treatment.
• He also noted that the company's data demonstrates that their gamma-delta T cell therapeutic approach in INB-100 and INB-200 can drive durable complete remissions compared to the current standard-of-care in certain aggressive cancers.

Industry Context

The announcement highlights the growing interest in gamma-delta T cell therapies as a novel approach to cancer treatment, particularly in areas with poor outcomes using standard treatments. The positive clinical data positions IN8bio as a leader in this emerging field, while the Nasdaq listing issue underscores the challenges faced by biotech companies in maintaining financial stability and market confidence.

Comparison to Industry Standards

• The 100% one-year complete remission rate in the INB-100 trial is a very strong result compared to typical outcomes for relapsed or refractory AML patients, where complete remission rates are often much lower with standard treatments like chemotherapy or stem cell transplants.
• The 92% progression-free survival rate exceeding seven months in the INB-200 trial for glioblastoma is also notable, as the median survival for GBM patients with standard treatment is typically around 12-15 months, and progression-free survival is often much shorter.
• Companies like Adaptimmune and Allogene Therapeutics are also developing cell therapies for cancer, but IN8bio's focus on gamma-delta T cells is a differentiator. Adaptimmune's focus is on engineered T-cell receptor therapies, and Allogene is focused on allogeneic CAR T-cell therapies.
• The manufacturing platform for gamma-delta T cells is a key differentiator for IN8bio, as the ability to produce a robust and reproducible product is critical for commercial success. This is a challenge for many cell therapy companies, and IN8bio's platform is a positive sign.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment if the company fails to regain compliance with Nasdaq listing requirements.
• Employees may be concerned about the company's financial stability and future prospects.
• Patients and the medical community may be encouraged by the positive clinical data, but the company's financial challenges could impact the development and availability of its therapies.
• Creditors may be concerned about the company's decreasing cash position.

Next Steps

• IN8bio will continue to monitor the closing bid price of its common stock.
• The company will evaluate available options to resolve the deficiency and regain compliance with the minimum bid price rule.
• IN8bio will continue to advance its gamma-delta T-cell programs.
• The company will provide additional updates on its gamma-delta T cell programs as it generates longer patient follow-up and advances its pipeline.

Key Dates

Keywords

IN8bio, gamma-delta T cells, cancer therapy, immunotherapy, clinical trials, INB-100, INB-200, hematologic malignancies, glioblastoma, Nasdaq, stock price, financial results